A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes

BACKGROUND: Given the multiple limitations associated with relatively homogeneous preapproval clinical trials, inadequate data disclosures, slow reaction times from regulatory bodies, and deep-rooted bias against disclosing and publishing negative results, there is an acute need for the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Keith B., Dimbil, Mo, Kyle, Robert F., Tatonetti, Nicholas P., Erdman, Colin B., Demakas, Andrea, Chen, Dingguo, Overstreet, Brian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397967/
https://www.ncbi.nlm.nih.gov/pubmed/26679963
http://dx.doi.org/10.18553/jmcp.2015.21.12.1134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397967/
https://www.ncbi.nlm.nih.gov/pubmed/26679963
http://dx.doi.org/10.18553/jmcp.2015.21.12.1134

Ejemplares similares